English
Regional settings| Spread | 3.6 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ SEK 5,000.00 Short position overnight fee ~ SEK 4,000.00 | -0.021938% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ SEK 5,000.00 Short position overnight fee ~ SEK 4,000.00 | -0.000284% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | SEK | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Sweden | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 117.5 |
| Open | 118.1 |
| 1-Year Change | 73.93% |
| Day's Range | 116.1 - 119.3 |
RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
BRIEF: For the fiscal year ended 31 December 2021, RaySearch Laboratories AB (publ) revenues decreased 2% to SEK641.1M. Net loss increased from SEK9.1M to SEK47.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenditure - B increase from SEK41K to SEK62.4M (expense), Amortization in R&D increase of 22% to SEK166.7M (expense).
June 2003: Capital restructuring, name changed from Taurus Petroleum AB to RaySearch and FY end date changed from Aug to Dec. Reverse stock split in the ratio 20:1, par value increased to SEK1.50 and a new issue of 4,212,607 A-Shares and 5,877,633 B-Shares. 06/2008, 3-for-1 stock split.
